Display options
Cite
Menay F, Herschlik L, De Toro J, et al. Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response. Front Immunol. 2017;8:286doi: 10.3389/fimmu.2017.00286.
Menay, F., Herschlik, L., De Toro, J., Cocozza, F., Tsacalian, R., Gravisaco, M. J., Di Sciullo, M. P., Vendrell, A., Waldner, C. I., & Mongini, C. (2017). Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response. Frontiers in immunology, 8286. https://doi.org/10.3389/fimmu.2017.00286
Menay, Florencia, et al. "Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response." Frontiers in immunology vol. 8 (2017): 286. doi: https://doi.org/10.3389/fimmu.2017.00286
Menay F, Herschlik L, De Toro J, Cocozza F, Tsacalian R, Gravisaco MJ, Di Sciullo MP, Vendrell A, Waldner CI, Mongini C. Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response. Front Immunol. 2017 Mar 16;8:286. doi: 10.3389/fimmu.2017.00286. eCollection 2017. PMID: 28360912; PMCID: PMC5352668.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Mar 16;8:286. doi: 10.3389/fimmu.2017.00286. eCollection 2017.

Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response.

Frontiers in immunology

Florencia Menay, Leticia Herschlik, Julieta De Toro, Federico Cocozza, Rodrigo Tsacalian, María José Gravisaco, María Paula Di Sciullo, Alejandrina Vendrell, Claudia I Waldner, Claudia Mongini

Affiliations

  1. Centro de Estudios Farmacológicos y Botánicos-Consejo Nacional de Investigaciones Científicas y Técnicas (CEFYBO-CONICET), Facultad de Medicina, Universidad de Buenos Aires , Buenos Aires , Argentina.
  2. Instituto Nacional de Tecnología Agropecuaria (INTA) , Buenos Aires , Argentina.
  3. Centro de Estudios Farmacológicos y Botánicos-Consejo Nacional de Investigaciones Científicas y Técnicas (CEFYBO-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina; Instituto Nacional de Tecnología Agropecuaria (INTA), Buenos Aires, Argentina.

PMID: 28360912 PMCID: PMC5352668 DOI: 10.3389/fimmu.2017.00286

Abstract

Extracellular vesicles (EVs), including endosome-derived nanovesicles (exosomes), are involved in cell-cell communication. Through transfer of their molecular contents, extracellular nanovesicles can alter the function of recipient cells. Due to these characteristics, EVs have shown potential as a new alternative for cancer immunotherapy. Tumor exosomes isolated from malignant ascites can activate dendritic cells, thereby priming the immune system to recognize and kill cancer cells. However, a suppressive role on tumor immune response has also been reported, suggesting that the neoplastic stage of carcinogenesis and the microenvironment where tumor cells grow may influence the amount of EVs released by the cell. This neoplastic stage and microenvironment may also impact EVs' components such as proteins and miRNA, determining their biological behavior. Most T-cell lymphomas have an aggressive clinical course and poor prognosis. Consequently, complementary alternative therapies are needed to improve the survival rates achieved with conventional treatments. In this work, we have characterized EVs isolated from ascites of mice bearing a very aggressive murine T-cell lymphoma and have studied their immunogenic properties. Small EVs were isolated by differential centrifugation, ultrafiltration, and ultracentrifugation at 100,000 × 

Keywords: T-cell lymphoma; ascites; exosomes; immune response; tumor vaccine

References

  1. In Vitro Cell Dev Biol Anim. 2001 Sep;37(8):499-504 - PubMed
  2. J Immunol Methods. 2001 Jan 1;247(1-2):163-74 - PubMed
  3. Front Oncol. 2013 Sep 25;3:256 - PubMed
  4. Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7 - PubMed
  5. J Cell Biol. 2013 Feb 18;200(4):373-83 - PubMed
  6. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77 - PubMed
  7. Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22 - PubMed
  8. Curr Oncol. 2009 May;16(3):46-9 - PubMed
  9. J Extracell Vesicles. 2013 Feb 15;2:null - PubMed
  10. Cancer Res. 2007 Apr 1;67(7):2912-5 - PubMed
  11. J Immunol. 2003 Mar 15;170(6):3037-45 - PubMed
  12. Nat Rev Drug Discov. 2013 May;12(5):347-57 - PubMed
  13. J Transl Med. 2005 Feb 21;3(1):9 - PubMed
  14. Cancer Res. 2007 Aug 1;67(15):7458-66 - PubMed
  15. Lancet. 2002 Jul 27;360(9329):295-305 - PubMed
  16. Cancer Immunol Immunother. 2011 May;60(5):639-48 - PubMed
  17. Vaccine. 2011 Jan 17;29(4):728-36 - PubMed
  18. Nat Protoc. 2006;1(3):1507-16 - PubMed
  19. Cancer Res. 2005 Dec 1;65(23):10783-93 - PubMed
  20. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  21. Nat Rev Immunol. 2002 Aug;2(8):569-79 - PubMed
  22. J Immunol. 2006 Feb 1;176(3):1375-85 - PubMed
  23. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41 - PubMed
  24. Blood Cells Mol Dis. 2005 Sep-Oct;35(2):129-35 - PubMed
  25. J Immunother. 2013 Apr;36(3):171-80 - PubMed
  26. Blood Cells Mol Dis. 2005 Sep-Oct;35(2):169-73 - PubMed
  27. PLoS One. 2010 Jul 22;5(7):e11469 - PubMed
  28. Am J Respir Cell Mol Biol. 2004 Jul;31(1):114-21 - PubMed
  29. Blood. 2009 Feb 26;113(9):1957-66 - PubMed
  30. Blood. 2007 Jun 1;109(11):4839-45 - PubMed
  31. J Cell Sci. 2005 Aug 15;118(Pt 16):3631-8 - PubMed
  32. J Mol Med (Berl). 2013 Apr;91(4):431-7 - PubMed
  33. Front Immunol. 2015 May 04;6:203 - PubMed
  34. Nat Protoc. 2007;2(9):2049-56 - PubMed
  35. Annu Rev Cell Dev Biol. 2014;30:255-89 - PubMed
  36. Int Immunopharmacol. 2005 Nov;5(12):1685-92 - PubMed
  37. J Immunol. 2011 Jan 1;186(1):73-82 - PubMed
  38. Nat Rev Immunol. 2014 Mar;14(3):195-208 - PubMed
  39. Mol Ther. 2008 Apr;16(4):782-90 - PubMed
  40. Biol Cell. 2006 Aug;98(8):491-501 - PubMed
  41. Cancer Res. 2010 Dec 1;70(23):9621-30 - PubMed

Publication Types